Advances in research on left ventricular hypertrophy-associated cardiovascular pathology in Alzheimer' s disease

doi:10.3969/j.issn.1674-8115.2025.12.014

Abstract

Abstract:

Left ventricular hypertrophy (LVH) is a form of myocardial remodeling characterized by thickening of left ventricular wall and increased myocardial mass. It is not only associated with the incidence and mortality of various cardiovascular diseases such as heart failure, coronary artery disease, and arrhythmias, but is also considered an independent risk factor for cognitive dysfunction. Alzheimer's disease (AD), the most common cause of dementia, is a neurodegenerative disorder of the central nervous system characterized by progressive cognitive impairment and behavioral deficits. Although the relationship between cardiovascular diseases and cognitive dysfunction has been widely investigated, the mechanisms through which LVH affects the core pathology of AD are not yet fully elucidated. This article provides a comprehensive systematic overview regarding the relationship between AD and cardiovascular diseases, the comorbidity of LVH and AD, and their direct pathological mechanisms, offering novel perspectives for advancing the exploration of heart-brain axis interactions.

Key words: left ventricular hypertrophy, Alzheimer's disease, cardiovascular disease

CLC Number:

R741.02

LUO Yuqi, WANG Yangyang, REN Jun. Advances in research on left ventricular hypertrophy-associated cardiovascular pathology in Alzheimer' s disease[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2025, 45(12): 1679-1686.

TrendMD

References 59

[1]	WONG M, DAI Y, GE J. Pan-vascular disease: what we have done in the past and what we can do in the future?[J]. Cardiol Plus, 2024, 9(1): 1-5.
[2]	SALARDINI A, HIMALI J J, ABDULLAH M S, et al. Elevated serum cortisol associated with early-detected increase of brain amyloid deposition in Alzheimer's disease imaging biomarkers among menopausal women: the Framingham Heart Study[J]. Alzheimers Dement, 2025, 21(4): e70179.
[3]	COGSWELL P M, FAN A P. Multimodal comparisons of QSM and PET in neurodegeneration and aging[J]. Neuroimage, 2023, 273: 120068.
[4]	ZHAO B, LI T, FAN Z, et al. Heart-brain connections: phenotypic and genetic insights from magnetic resonance images[J]. Science, 2023, 380(6648): abn6598.
[5]	HUANG Z, SUN A. Metabolism, inflammation, and cardiovascular diseases from basic research to clinical practice[J]. Cardiol Plus, 2023, 8(1): 4-5.
[6]	KIRBY A, PORTER T, ADEWUYI E O, et al. Investigating genetic overlap between Alzheimer's disease, lipids, and coronary artery disease: a large-scale genome-wide cross trait analysis[J]. Int J Mol Sci, 2024, 25(16): 8814.
[7]	ISLAM M R, LBIK D, SAKIB M S, et al. Epigenetic gene expression links heart failure to memory impairment[J]. EMBO Mol Med, 2021, 13(3): e11900.
[8]	DRIDI H, LIU Y, REIKEN S, et al. Heart failure-induced cognitive dysfunction is mediated by intracellular Ca²⁺ leak through ryanodine receptor type 2[J]. Nat Neurosci, 2023, 26(8): 1365-1378.
[9]	TAI X Y, VELDSMAN M, LYALL D M, et al. Cardiometabolic multimorbidity, genetic risk, and dementia: a prospective cohort study[J]. Lancet Healthy Longev, 2022, 3(6): e428-e436.
[10]	DE ANDA-DURAN I, WOLTZ S G, BELL C N, et al. Hypertension and cognitive function: a review of life-course factors and disparities[J]. Curr Opin Cardiol, 2022, 37(4): 326-333.
[11]	HU H, MENG L, BI Y L, et al. Tau pathologies mediate the association of blood pressure with cognitive impairment in adults without dementia: the CABLE study[J]. Alzheimers Dement, 2022, 18(1): 53-64.
[12]	SIEDLINSKI M, CARNEVALE L, XU X G, et al. Genetic analyses identify brain structures related to cognitive impairment associated with elevated blood pressure[J]. Eur Heart J, 2023, 44(23): 2114-2125.
[13]	TAKAHASHI M K N, PARADELA R S, GRINBERG L T, et al. Hypertension may associate with cerebral small vessel disease and infarcts through the pathway of intracranial atherosclerosis[J]. Neurobiol Aging, 2025, 145: 84-95.
[14]	KURZ C, WALKER L, RAUCHMANN B S, et al. Dysfunction of the blood-brain barrier in Alzheimer's disease: evidence from human studies[J]. Neuropathol Appl Neurobiol, 2022, 48(3): e12782.
[15]	LORENZINI L, MARANZANO A, INGALA S, et al. Association of vascular risk factors and cerebrovascular pathology with Alzheimer disease pathologic changes in individuals without dementia[J]. Neurology, 2024, 103(7): e209801.
[16]	SHIH Y H, WU S Y, YU M, et al. Hypertension accelerates Alzheimer's disease-related pathologies in pigs and 3xTg mice[J]. Front Aging Neurosci, 2018, 10: 73.
[17]	FARACO G, PARK L, ZHOU P, et al. Hypertension enhances Aβ- induced neurovascular dysfunction, promotes β-secretase activity, and leads to amyloidogenic processing of APP[J]. J Cereb Blood Flow Metab, 2016, 36(1): 241-252.
[18]	SIBLE I J, YEW B, JANG J Y, et al. Blood pressure variability and plasma Alzheimer's disease biomarkers in older adults[J]. Sci Rep, 2022, 12(1): 17197.
[19]	UCHIDA Y, NISHIMAKI K, SOLDAN A, et al. Acceleration of brain atrophy and progression from normal cognition to mild cognitive impairment[J]. JAMA Netw Open, 2024, 7(10): e2441505.
[20]	DING X, YIN L, ZHANG L, et al. Diabetes accelerates Alzheimer's disease progression in the first year post mild cognitive impairment diagnosis[J]. Alzheimers Dement, 2024, 20(7): 4583-4593.
[21]	DOVE A, SHANG Y, XU W, et al. The impact of diabetes on cognitive impairment and its progression to dementia[J]. Alzheimers Dement, 2021, 17(11): 1769-1778.
[22]	BIRAJDAR S V, MAZAHIR F, ALAM M I, et al. Repurposing and clinical attributes of antidiabetic drugs for the treatment of neurodegenerative disorders[J]. Eur J Pharmacol, 2023, 961: 176117.
[23]	FIŠAR Z. Linking the amyloid, tau, and mitochondrial hypotheses of Alzheimer's disease and identifying promising drug targets[J]. Biomolecules, 2022, 12(11): 1676.
[24]	ABBAS K, MUSTAFA M, ALAM M, et al. Multi-target approach to Alzheimer's disease prevention and treatment: antioxidant, anti-inflammatory, and amyloid-modulating mechanisms[J]. Neurogenetics, 2025, 26(1): 39.
[25]	SHARP F R, DECARLI C S, JIN L W, et al. White matter injury, cholesterol dysmetabolism, and APP/Aβ dysmetabolism interact to produce Alzheimer's disease (AD) neuropathology: a hypothesis and review[J]. Front Aging Neurosci, 2023, 15: 1096206.
[26]	WINGO A P, VATTATHIL S M, LIU J, et al. LDL cholesterol is associated with higher AD neuropathology burden independent of APOE[J]. J Neurol Neurosurg Psychiatry, 2022: jnnp-2021-328164.
[27]	WONGCHITRAT P, CHANMEE T, GOVITRAPONG P. Molecular mechanisms associated with neurodegeneration of neurotropic viral infection[J]. Mol Neurobiol, 2024, 61(5): 2881-2903.
[28]	SULTANA O F, HIA R A, REDDY P H. A combinational therapy for preventing and delaying the onset of Alzheimer's disease: a focus on probiotic and vitamin co-supplementation[J]. Antioxidants (Basel), 2024, 13(2): 202.
[29]	MATSUMOTO T, TAGUCHI K, KOBAYASHI T. Relationships between advanced glycation end products (AGEs), vasoactive substances, and vascular function[J]. J Smooth Muscle Res, 2021, 57(0): 94-107.
[30]	MA Y F, MA Z M, ZHANG Y Y, et al. Apigenin and baicalein ameliorate thoracic aortic structural deterioration and cognitive deficit via inhibiting AGEs/RAGE/NF-κB pathway in D-galactose-induced aging rats[J]. Eur J Pharmacol, 2024, 976: 176660.
[31]	FIŠAR Z, HROUDOVÁ J. CoQ₁₀ and mitochondrial dysfunction in Alzheimer's disease[J]. Antioxidants (Basel), 2024, 13(2): 191.
[32]	CICEU A, BALTA C, HERMAN H, et al. Complexation with random methyl-β-cyclodextrin and (2-hidroxypropyl)-β-cyclodextrin enhances in vivo anti-fibrotic and anti-inflammatory effects of chrysin via the inhibition of NF-κB and TGF-β1/smad signaling pathways and modulation of hepatic pro/anti-fibrotic miRNA[J]. Int J Mol Sci, 2021, 22(4): 1869.
[33]	KHAN Z, SULEMAN M, MAQSOOD A, et al. Unveiling cardiovascular connections between familial hypercholesterolemia (FH) and left ventricular hypertrophy (LVH)[J]. BioSci Rev, 2024, 6(1): 54-69.
[34]	WANG W, WANG Q, QI X, et al. Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: target trial emulation using nationwide real-world data in the US [J]. Alzheimers Dement, 2024, 20(12): 8661-8672.
[35]	NAGARAJA N, FAROOQUI A, ALBAYRAM M S. Association of deep white matter hyperintensity with left ventricular hypertrophy in acute ischemic stroke[J]. J Neuroimaging, 2022, 32(2): 268-272.
[36]	PAPADOPOULOS A, PALAIOPANOS K, PROTOGEROU A P, et al. Left ventricular hypertrophy and cerebral small vessel disease: a systematic review and meta-analysis[J]. J Stroke, 2020, 22(2): 206-224.
[37]	LI Q, SU S, FENG Y, et al. Potential role of blood pressure variability and plasma neurofilament light in the mechanism of comorbidity between Alzheimer's disease and cerebral small vessel disease[J]. Alzheimers Dement, 2024, 20(7): 4891-4902.
[38]	BEACH T G, SUE L I, SCOTT S, et al. Cerebral white matter rarefaction has both neurodegenerative and vascular causes and may primarily be a distal axonopathy[J]. J Neuropathol Exp Neurol, 2023, 82(6): 457-466.
[39]	MANCA R, JONES S A, VENNERI A. Macrostructural and microstructural white matter alterations are associated with apathy across the clinical Alzheimer's disease spectrum[J]. Brain Sci, 2022, 12(10): 1383.
[40]	FENG T, YAMASHITA T, SASAKI R, et al. Protective effects of edaravone on white matter pathology in a novel mouse model of Alzheimer's disease with chronic cerebral hypoperfusion[J]. J Cereb Blood Flow Metab, 2021, 41(6): 1437-1448.
[41]	HU H Y, HU H, JIANG J, et al. Echocardiographic measures of the left heart and cerebrospinal fluid biomarkers of Alzheimer's disease pathology in cognitively intact adults: the CABLE study[J]. Alzheimers Dement, 2024, 20(6): 3943-3957.
[42]	YE J, WAN H, CHEN S, et al. Targeting tau in Alzheimer's disease: from mechanisms to clinical therapy[J]. Neural Regen Res, 2024, 19(7): 1489-1498.
[43]	SAMLUK L, OSTAPCZUK P, DZIEMBOWSKA M. Long-term mitochondrial stress induces early steps of Tau aggregation by increasing reactive oxygen species levels and affecting cellular proteostasis[J]. Mol Biol Cell, 2022, 33(8): ar67.
[44]	SETHI P, C R D, BORRA R, et al. Mechanistic insights into tau protein-mediated regulation of oxidative stress[J]. Chin J Appl Physiol, 2024, 40: e20240028.
[45]	ZHANG Y L, ZHANG Y, AMAN Y, et al. Amyloid-β toxicity modulates tau phosphorylation through the PAX6 signalling pathwayFree[J]. Brain, 2021, 144(9): 2759-2770.
[46]	XU X, MO X, ZHANG W, et al. Local and distant atrophy mediate the relationship between tau pathology and cognition in temporoparietal region in Alzheimer's disease[J]. J Alzheimers Dis, 2025, 104(4): 1092-1102.
[47]	GORANTLA N V, CHINNATHAMBI S. Autophagic pathways to clear the tau aggregates in Alzheimer's disease[J]. Cell Mol Neurobiol, 2021, 41(6): 1175-1181.
[48]	WANG W, LU L, WU Q Q, et al. Brain amyloid-β plays an initiating role in the pathophysiological process of the PS1V97L-tg mouse model of Alzheimer's disease[J]. J Alzheimers Dis, 2016, 52(3): 1089-1099.
[49]	HAQUE M M, MURALE D P, KIM Y K, et al. Crosstalk between oxidative stress and tauopathy[J]. Int J Mol Sci, 2019, 20(8): E1959.
[50]	MEANS J C, LOPEZ A A, KOULEN P. Resveratrol protects optic nerve head astrocytes from oxidative stress-induced cell death by preventing caspase-3 activation, tau dephosphorylation at Ser422 and formation of misfolded protein aggregates[J]. Cell Mol Neurobiol, 2020, 40(6): 911-926.
[51]	PRASAD H, RAO R. Endosomal acid-base homeostasis in neurodegenerative diseases[J]. Rev Physiol Biochem Pharmacol, 2023, 185: 195-231.
[52]	XU X D, TENG Y, ZOU J Y, et al. Effects of lycopene on vascular remodeling through the LXR-PI3K-AKT signaling pathway in APP/PS1 mice[J]. Biochem Biophys Res Commun, 2020, 526(3): 699-705.
[53]	LI Y, NI N, LEE M, et al. Endothelial leakiness elicited by amyloid protein aggregation[J]. Nat Commun, 2024, 15(1): 613.
[54]	ZHAO J, LANG M. New insight into protein glycosylation in the development of Alzheimer's disease[J]. Cell Death Discov, 2023, 9(1): 314.
[55]	VERSELE R, SEVIN E, GOSSELET F, et al. TNF-α and IL-1β modulate blood-brain barrier permeability and decrease amyloid-β peptide efflux in a human blood-brain barrier model[J]. Int J Mol Sci, 2022, 23(18): 10235.
[56]	ANDERSON G, MAZZOCCOLI G. Left ventricular hypertrophy: roles of mitochondria CYP1B1 and melatonergic pathways in co-ordinating wider pathophysiology[J]. Int J Mol Sci, 2019, 20(16): E4068.
[57]	BIR A, GHOSH A, CHAUHAN A, et al. Exosomal dynamics and brain redox imbalance: implications in Alzheimer's disease pathology and diagnosis[J]. Antioxidants (Basel), 2024, 13(3): 316.
[58]	ROEMER-CASSIANO S N, WAGNER F, EVANGELISTA L, et al. Amyloid-associated hyperconnectivity drives tau spread across connected brain regions in Alzheimer's disease[J]. Sci Transl Med, 2025, 17(782): eadp2564.
[59]	ROHNER M H, GEBHARD C, LUFT A, et al. Cardiac findings following cerebrovascular disease[J]. J Am Heart Assoc, 2024, 13(17): e034131.